A Chemotherapy-Free Regimen of Tucatinib and Trastuzumab Shows Antitumour Activity with Durable Responses in Patients with HER2-mutated MBC By Ogkologos - January 29, 2025 793 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SGNTUC-019 study Source RELATED ARTICLESMORE FROM AUTHOR Tambotatug Pelitecan Leads to Better Clinical Outcomes than Topotecan Among Patients with Relapsed SCLC After Platinum-based Therapy ESMO Welcomes European Parliament Calls to Strengthen and Protect Europe’s Cancer Workforce No improvement in OS, but more grade 3 or higher AEs with atezolizumab plus SBRT among patients with inoperable early-stage NSCLC MOST POPULAR Vorasidenib Treatment Shows Promise for Some Low-Grade Gliomas June 27, 2023 Savolitinib Shows Promise in Pulmonary Sarcomatoid Carcinoma and Other METex14-positive NSCLC... June 23, 2021 NHS England change of chief executive – what does it mean... August 19, 2021 Living With Metastatic Breast Cancer: How I Reinvented Myself October 30, 2020 Load more HOT NEWS Lion With Skin Cancer Has Received Radiation Therapy In Hospital Neoadjuvant Followed by Adjuvant Pembrolizumab Prolongs Event-Free Survival Compared to Adjuvant... Adjuvant Imatinib Prolongs RFS and OS in Patients with Resected GIST... Opinion: ‘We’re speaking with One Cancer Voice, but is anyone listening?’
